Mitochondrial Peptides Research Guide: MOTS-c, Humanin, SS-31 and Cellular Energy

Introduction: Your Mitochondria Are Talking — These Peptides Are the Message

For decades, mitochondria were viewed as simple cellular power plants — organelles whose sole job was converting food into ATP. That view has been completely transformed by the discovery of mitochondrial-derived peptides (MDPs): small bioactive peptides encoded within the mitochondrial genome that function as systemic signaling molecules, communicating mitochondrial health status to the rest of the cell and body.

Most people in the peptide research community know MOTS-c, the 16-amino acid exercise mimetic that has become the poster child for mitochondrial peptide research. But MOTS-c is just the tip of the iceberg. The mitochondrial genome encodes at least eight distinct bioactive peptides — including humanin, six small humanin-like peptides (SHLP1-6), and MOTS-c — each with unique biological activities that collectively represent one of the most exciting frontiers in longevity and metabolic research.

These peptides challenge fundamental assumptions about cellular signaling. They suggest that mitochondria are not passive organelles but active communicators, broadcasting distress signals when stressed and protective signals when healthy. Understanding this “mitochondrial language” could transform how we approach aging, neurodegeneration, metabolic disease, and cellular resilience.

What Are Mitochondrial-Derived Peptides (MDPs)?

Mitochondrial-derived peptides are small open reading frame (sORF)-encoded peptides found within the mitochondrial DNA (mtDNA). Unlike the 13 well-characterized proteins encoded by mtDNA (which are all components of the electron transport chain), MDPs are encoded within ribosomal RNA (rRNA) genes — regions previously thought to be exclusively structural.

The discovery that rRNA genes could harbor functional peptide-coding sequences was paradigm-shifting. It suggested that the mitochondrial genome contains significantly more functional information than previously appreciated, with a second “layer” of coding capacity hidden within structural RNA genes.

MOTS-c: The Flagship MDP (Quick Recap)

Before diving into the lesser-known MDPs, a brief recap of MOTS-c provides essential context. Discovered by Changhan David Lee at the University of Southern California in 2015, MOTS-c is a 16-amino acid peptide encoded in the mitochondrial 12S rRNA gene. It activates AMPK, the cell’s master energy sensor, and reproduces many metabolic effects of exercise: improved insulin sensitivity, enhanced glucose uptake, increased fatty acid oxidation, and resistance to diet-induced obesity (PMID: 25738459).

MOTS-c has the most extensive research base of any MDP (after humanin) and is commercially available as a research peptide from suppliers like Proxiva Labs. For comprehensive MOTS-c coverage, see our detailed MOTS-c research guide.

Humanin: The Original Mitochondrial Survival Signal

Humanin (HN) holds the distinction of being the first mitochondrial-derived peptide ever discovered. Identified in 2001 by Hashimoto et al. through a functional screening approach, humanin was found in an unbiased search for cDNAs that could protect neurons from death induced by familial Alzheimer’s disease-linked proteins (PMID: 11454738).

Structure and Variants

Humanin is a 24-amino acid peptide (sequence: MAPRGFSCLLLLTSEIDLPVKRRA) encoded within the 16S ribosomal RNA gene of the mitochondrial genome. Since its discovery, several synthetic analogs with enhanced potency have been developed:

• [Gly14]-Humanin (HNG): A single amino acid substitution (Ser14?Gly14) that increases neuroprotective potency approximately 1000-fold
• Humanin G (S14G): The most commonly used potent analog in research
• Colivelin: A hybrid peptide combining activity-dependent neurotrophic factor (ADNF) with a humanin derivative, showing picomolar neuroprotective activity

Expression and Circulation

Humanin is both produced locally within cells (from mitochondrial transcription) and found in the systemic circulation, where it functions as a circulating hormone-like factor. Plasma humanin levels can be measured by ELISA and have been shown to correlate with age, metabolic status, and disease states. Notably, humanin levels are found in multiple body fluids including plasma, cerebrospinal fluid, and seminal fluid, suggesting diverse tissue sources and functions.

Humanin Mechanism of Action: IGFBP-3, BAX, and STAT3

Humanin exerts its biological effects through at least three well-characterized molecular mechanisms:

1. IGFBP-3 Interaction

Humanin binds to insulin-like growth factor binding protein-3 (IGFBP-3) and inhibits its pro-apoptotic activity. IGFBP-3, independent of its role in IGF binding, can translocate to the nucleus and directly induce apoptosis in certain cell types. By binding and sequestering IGFBP-3, humanin prevents this nuclear translocation and protects cells from IGFBP-3-mediated death. This interaction is particularly relevant in the context of Alzheimer’s disease, where IGFBP-3 levels are elevated and may contribute to neuronal death (PMID: 12736270).

2. BAX Binding (Anti-Apoptotic)

Humanin directly binds to BAX, a pro-apoptotic member of the BCL-2 protein family. BAX normally translocates to the outer mitochondrial membrane during apoptosis, where it forms pores that release cytochrome c and trigger the intrinsic apoptotic cascade. By binding BAX and preventing its mitochondrial translocation, humanin blocks the terminal execution phase of apoptosis. This is an intracellular mechanism that requires humanin to be present within the cell (PMID: 15713625).

3. FPRL1/FPRL2 Receptor Binding (Extracellular)

Humanin binds to formyl peptide receptor-like 1 and 2 (FPRL1/FPRL2, now known as FPR2/FPR3) on the cell surface. These G protein-coupled receptors activate intracellular signaling cascades including the JAK2/STAT3 pathway, which promotes cell survival, reduces inflammation, and modulates immune responses. This extracellular mechanism allows humanin to act as a circulating survival factor, protecting distant tissues from stress-induced death.

4. gp130/CNTFR/WSX-1 Trimeric Receptor

Humanin also signals through a trimeric receptor complex consisting of gp130, CNTF receptor alpha (CNTFR), and WSX-1 (IL-27 receptor alpha). This receptor complex activates STAT3 signaling and represents a distinct mechanism from FPRL1/2 binding. The trimeric receptor may mediate humanin’s metabolic effects, including insulin sensitization (PMID: 19628736).

Humanin and Aging: Declining Levels, Rising Disease

Circulating humanin levels decline significantly with age, paralleling the decline in mitochondrial function that characterizes aging. This decline has been documented in multiple studies:

• Age-related decline: Plasma humanin levels decrease approximately 40% between young adulthood and old age in human cross-sectional studies
• Centenarian paradox: Interestingly, centenarians and their offspring tend to have higher humanin levels than age-matched controls, suggesting that maintained humanin production may be a marker (or mediator) of exceptional longevity
• GH/IGF-1 axis: Humanin levels inversely correlate with growth hormone and IGF-1 levels. Mice with reduced GH/IGF-1 signaling (which are long-lived) have elevated humanin levels, suggesting that humanin may mediate some of the longevity benefits of reduced growth hormone signaling
• Mitochondrial DNA copy number: Humanin levels correlate with mtDNA copy number, which itself declines with age. This makes mechanistic sense — fewer mitochondrial genomes means less humanin transcription

The correlation between declining humanin and the onset of age-related diseases has led to the hypothesis that humanin is an endogenous “resilience factor” — a signal that communicates mitochondrial health to the rest of the organism and that, when deficient, contributes to the vulnerability of aging tissues to stress and disease.

Humanin in Neurodegeneration: Alzheimer’s and Beyond

Humanin was discovered through its neuroprotective activity, and neurodegeneration remains its best-characterized research application:

Alzheimer’s Disease

• Humanin protects neurons from toxicity induced by all known familial AD-linked proteins: amyloid-beta (A?), presenilin-1 (PS1), and presenilin-2 (PS2) mutants
• The potent analog HNG (S14G-humanin) prevents A?-induced neuronal death at picomolar concentrations
• In AD mouse models, humanin administration improves cognitive function, reduces amyloid plaque burden, and protects hippocampal neurons
• Cerebrospinal fluid humanin levels are reduced in AD patients compared to controls, suggesting that endogenous humanin deficiency may contribute to disease progression

Other Neurodegenerative Conditions

• Parkinson’s disease: Humanin protects dopaminergic neurons from MPTP and rotenone toxicity in preclinical models
• Huntington’s disease: Protection against mutant huntingtin-induced mitochondrial dysfunction and cell death
• Stroke: Humanin administration reduces infarct volume and improves neurological outcomes in rodent stroke models
• Prion disease: Protection against prion protein-induced neurotoxicity in cell culture

The breadth of humanin’s neuroprotective activity across multiple disease models suggests it targets a common downstream vulnerability — mitochondrial dysfunction and the intrinsic apoptotic pathway — rather than addressing disease-specific pathology. This makes it a fundamentally different neuroprotective strategy from disease-specific approaches (e.g., anti-amyloid antibodies for AD).

For researchers interested in neuroprotective peptides, Selank and Semax represent complementary nootropic approaches with different mechanisms (BDNF upregulation, GABA modulation) that could potentially be combined with mitochondrial peptides for multi-target neuroprotection strategies.

Humanin in Metabolic Disease and Insulin Sensitivity

Beyond neuroprotection, humanin has demonstrated significant metabolic effects:

Insulin Sensitization

Humanin improves insulin sensitivity through its trimeric receptor complex (gp130/CNTFR/WSX-1) and downstream STAT3 signaling. In diet-induced obese mice, humanin analog administration improved glucose tolerance and insulin sensitivity without affecting food intake or body weight — suggesting a direct effect on insulin signaling pathways rather than an indirect effect through weight loss (PMID: 24452282).

Beta Cell Protection

Humanin protects pancreatic beta cells from stress-induced apoptosis, including glucolipotoxicity (the combination of high glucose and high fatty acid exposure that damages beta cells in type 2 diabetes). This cytoprotective effect could theoretically help preserve insulin-producing capacity in metabolic disease.

Cardiovascular Protection

Humanin has demonstrated cardioprotective effects in ischemia-reperfusion models, reducing infarct size and preserving cardiac function. The mechanism involves both direct anti-apoptotic effects on cardiomyocytes and improved endothelial function through enhanced NO signaling.

Anti-Inflammatory Effects

Humanin suppresses NF-?B activation and reduces pro-inflammatory cytokine production in multiple cell types. Given the role of chronic inflammation in metabolic disease, neurodegeneration, and aging, this anti-inflammatory activity may be a significant component of humanin’s protective effects across diverse disease models.

The SHLP Family: Six Small Humanin-Like Peptides

In 2016, Pinchas Cohen’s laboratory at USC (the same group that discovered MOTS-c) identified six additional peptide-coding sORFs within the 16S rRNA gene of mtDNA — the same gene that encodes humanin. These were named Small Humanin-Like Peptides 1-6 (SHLP1-6) (PMID: 27634869).

The discovery of six additional peptides from a single mitochondrial gene suggests an even more complex mitochondrial signaling system than previously imagined. Each SHLP has a distinct biological activity profile, despite being encoded in adjacent regions of the same gene:

SHLP2: The Insulin Sensitizer With Cytoprotective Properties

SHLP2 is the most extensively characterized member of the SHLP family and has emerged as a particularly promising research target. Key findings include:

Insulin Sensitization

SHLP2 demonstrates potent insulin-sensitizing activity in preclinical models. Treatment with SHLP2 improves glucose tolerance and reduces fasting insulin levels in diet-induced obese mice. The mechanism appears to involve enhanced insulin receptor signaling and improved glucose transporter (GLUT4) translocation to the cell surface in skeletal muscle and adipose tissue.

Mitochondrial Protection

SHLP2 directly protects mitochondria from oxidative stress-induced dysfunction. It preserves mitochondrial membrane potential, prevents cytochrome c release, and maintains electron transport chain efficiency under conditions that would normally trigger mitochondrial collapse. This mitochondrial-specific protective effect distinguishes SHLP2 from many other cytoprotective peptides that act primarily at the cell membrane or cytoplasmic level.

Anti-Apoptotic Activity

Like humanin, SHLP2 exhibits anti-apoptotic properties, protecting cells from both intrinsic (mitochondrial) and extrinsic (death receptor) apoptotic pathways. However, the specific molecular targets differ from humanin’s, suggesting complementary rather than redundant protective mechanisms.

Age-Related Decline

Circulating SHLP2 levels decline with age, paralleling the decline in humanin and MOTS-c. This coordinated decline across multiple MDPs strengthens the hypothesis that mitochondrial signaling capacity decreases with age, contributing to the loss of cellular resilience that characterizes the aging phenotype.

Cancer Biology

Intriguingly, SHLP2 has shown anti-cancer properties in certain models. It reduces prostate cancer cell proliferation and promotes differentiation in cell culture studies. This anti-cancer activity, combined with its cytoprotective effects in normal cells, suggests a “selective protection” mechanism where SHLP2 promotes survival of healthy cells while inhibiting growth of transformed cells.

SHLP6: The Pro-Apoptotic Outlier

Among the eight known MDPs, SHLP6 is uniquely pro-apoptotic — it promotes cell death rather than preventing it. This surprising finding challenges the assumption that all mitochondrial peptides function as survival factors:

• SHLP6 induces apoptosis in cancer cell lines at concentrations that do not affect normal cells
• It promotes ROS (reactive oxygen species) generation and mitochondrial membrane depolarization
• The pro-apoptotic mechanism appears to involve BAX activation and cytochrome c release — the opposite of humanin’s BAX-inhibiting mechanism

The existence of both pro-survival (humanin, SHLP2) and pro-death (SHLP6) MDPs encoded in the same mitochondrial gene suggests a sophisticated quality control system. The balance between these opposing signals may determine whether a stressed cell is rescued (if the damage is repairable) or eliminated (if the damage is irreparable and the cell poses a risk of malignant transformation).

SHLP1, SHLP3, SHLP4, SHLP5: Emerging Profiles

SHLP1

SHLP1 has been shown to possess chaperone-like activity, helping misfolded proteins refold correctly. This is particularly relevant in neurodegenerative diseases where protein misfolding (amyloid-beta in AD, alpha-synuclein in PD, tau) is a central pathological feature. SHLP1 also exhibits anti-apoptotic properties and may contribute to mitochondrial protein homeostasis (proteostasis).

SHLP3

SHLP3 demonstrates anti-apoptotic and mitochondrial protective effects similar to SHLP2 but with potentially different potency and tissue specificity. It has been shown to improve mitochondrial respiration in stressed cells and may have particular relevance for cardiac and skeletal muscle mitochondrial function.

SHLP4

Less well-characterized than SHLP2 and SHLP3, SHLP4 has been linked to cell proliferation effects. Its role in normal physiology and disease contexts is still being defined, and it represents an early-stage research target.

SHLP5

SHLP5 has been associated with enhanced mitochondrial respiration, specifically improving Complex I and Complex III activity in the electron transport chain. This could make it particularly relevant for conditions involving electron transport chain dysfunction, such as mitochondrial myopathies and age-related mitochondrial decline.

MDP Retrograde Signaling: How Mitochondria Talk to the Nucleus

One of the most paradigm-shifting aspects of MDP biology is the concept of mitochondrial retrograde signaling — communication from mitochondria to the nucleus that alters nuclear gene expression in response to mitochondrial stress or status.

Traditional cell biology described a one-way communication: the nucleus sends instructions to mitochondria (through nuclear-encoded mitochondrial proteins). MDPs reveal that this communication is bidirectional:

1. Mitochondrial stress/status assessment: Changes in mitochondrial function (ROS production, membrane potential, respiratory chain efficiency, mtDNA integrity) alter the transcription and translation of MDPs within the mitochondrial matrix
2. MDP export: MDPs are exported from mitochondria through mechanisms that are still being characterized (possibly involving the mitochondrial unfolded protein response, UPRmt, and specific transport machinery)
3. Intracellular signaling: Within the cell, MDPs can act directly (humanin binding BAX) or through signaling cascades (MOTS-c activating AMPK) to alter cellular metabolism and gene expression
4. Systemic signaling: MDPs are also secreted into the bloodstream, where they function as “mitokines” — mitochondria-derived hormones that communicate mitochondrial status to distant organs

This retrograde signaling system has profound implications for understanding aging. As mitochondrial function declines with age, MDP production decreases, potentially silencing the protective signals that normally help cells resist stress and maintain function. Exogenous MDP administration could theoretically restore these protective signals, even in cells with compromised mitochondria.

MDPs as Biomarkers of Aging: The Decline Curve

All major MDPs (humanin, MOTS-c, SHLP2) decline with age in human studies. This coordinated decline tracks with other markers of mitochondrial aging:

Researchers at USC have proposed using MDP levels as a composite biomarker panel for mitochondrial aging — the “mitoAge” score. This could potentially provide a more accurate measure of biological age than chronological age and could be used to track the effectiveness of anti-aging interventions. Studies exploring MDP levels alongside NAD+ supplementation strategies could help determine whether boosting NAD+ also restores MDP production.

MDPs and Exercise: The Mitokine Connection

Exercise is the most potent natural stimulus for MDP production. Acute exercise increases circulating MOTS-c levels by 50-100% in human subjects, and regular exercise training maintains higher baseline MDP levels compared to sedentary individuals (PMID: 31199915).

This exercise-MDP connection has led to the concept of MDPs as “mitokines” — exercise-induced factors released from mitochondria that mediate systemic metabolic benefits. The model proposes that exercise stresses mitochondria in working muscle, stimulating MDP transcription and release, which then signals to distant organs (liver, brain, adipose tissue, pancreas) to adapt their metabolism to the exercise state.

This framework directly connects to exercise mimetic research. Compounds like SLU-PP-332 (ERR? agonist) activate many of the same transcriptional programs as exercise, and may similarly stimulate MDP production. The combination of exercise mimetics with exogenous MDP administration could potentially create a comprehensive “exercise signal” that reaches organs and tissues even in sedentary or mobility-limited individuals.

Combination Strategies: MDPs + NAD+ + Exercise Mimetics

The emerging understanding of mitochondrial signaling suggests several rational combination strategies for aging and metabolic research:

Strategy 1: MDP Replacement + NAD+ Restoration

Combining exogenous MDPs (MOTS-c, humanin analogs) with NAD+ restoration strategies (5-Amino-1MQ for NNMT inhibition + NMN supplementation) addresses both the signaling deficit (declining MDPs) and the metabolic deficit (declining NAD+) that characterize aging mitochondria.

Strategy 2: Exercise Mimetics + MDP Support

Exercise mimetics like SLU-PP-332 activate exercise-responsive transcriptional programs, while exogenous MOTS-c provides the mitokine signal that exercise normally generates. Together, they could create a more complete “exercise state” than either alone.

Strategy 3: Multi-MDP Combinations

Given that each MDP has distinct biological activities, combining humanin (neuroprotection, anti-apoptosis) with MOTS-c (AMPK activation, metabolic regulation) could provide broader mitochondrial support than either peptide alone. This multi-MDP approach mirrors the natural state of youth, where all MDPs are produced at high levels simultaneously.

Strategy 4: MDPs + Senolytics

Senescent cells are a major source of inflammation that drives CD38 upregulation, NAD+ depletion, and mitochondrial dysfunction. Combining senolytic compounds (which clear senescent cells) with MDPs (which support mitochondrial function in remaining cells) could produce synergistic anti-aging effects by addressing both the damage source and the resilience deficit simultaneously.

Frequently Asked Questions

References

1. Hashimoto Y, Niikura T, Tajima H, et al. A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer’s disease genes and A?. Proc Natl Acad Sci USA. 2001;98(11):6336-6341. PMID: 11454738
2. Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454. PMID: 25738459
3. Cobb LJ, Lee C, Xiao J, et al. Naturally occurring mitochondrial-derived peptides are age-dependent regulators of apoptosis, insulin sensitivity, and inflammatory markers. Aging. 2016;8(4):796-809. PMID: 27634869
4. Guo B, Zhai D, Cabezas E, et al. Humanin peptide suppresses apoptosis by interfering with Bax activation. Nature. 2003;423(6938):456-461. PMID: 12736270
5. Zhai D, Bhatt S, Reed JC, et al. Humanin binds and nullifies Bid activity by blocking its activation of Bax and Bak. J Biol Chem. 2005;280(16):15815-15824. PMID: 15713625
6. Muzumdar RH, Huffman DM, Calvert JW, et al. Acute humanin therapy attenuates myocardial ischemia and reperfusion injury in mice. Arterioscler Thromb Vasc Biol. 2010;30(10):1940-1948. PMID: 20651281
7. Muzumdar RH, Huffman DM, Atzmon G, et al. Humanin: a novel central regulator of peripheral insulin action. PLoS One. 2009;4(7):e6334. PMID: 19623253
8. Kim KH, Son JM, Benayoun BA, Lee C. The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress. Cell Metab. 2018;28(3):516-524. PMID: 30043754
9. Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470. PMID: 33473109
10. Yen K, Lee C, Mehta H, Cohen P. The emerging role of the mitochondrial-derived peptide humanin in stress resistance. J Mol Endocrinol. 2013;50(1):R11-R19. PMID: 23239898
11. Niikura T, Sidahmed E, Bhatt M, et al. A tripartite motif protein TRIM11 is up-regulated in brain during aging and neurodegenerative conditions and binds humanin through a UBL-domain. J Neurochem. 2011;118(4):651-661.
12. Tajima H, Niikura T, Hashimoto Y, et al. Evidence for in vivo production of Humanin peptide, a neuroprotective factor against Alzheimer’s disease-related insults. Neurosci Lett. 2002;324(3):227-231.

About Proxiva Labs: We supply premium research-grade mitochondrial and metabolic peptides including MOTS-c, 5-Amino-1MQ, SLU-PP-332, and NAD+ Nasal Spray for qualified researchers. Browse our full research compound catalog.